RNA and protein analysis of α-synuclein expression following in vivo SNCA siRNA treatment. The right CA1 was infused with either PBS, siRNA to luciferase, or siRNA against our SNCA target. A typical SNCA in situ from an animal treated with (A) PBS or (B) SNCA siRNA on the right side compared to the uninjected left sides. While the cannula tract was evident in the right hippocampi of the infused mice (* in C and F), regardless of treatment group, (C) immunostaining for α-synuclein demonstrates considerable knockdown of protein expression (arrowhead) in the hippocampus when the uninjected control side is compared to the SNCA siRNA-treated side, also shown in higher magnification (D, E), respectively. (F) Inflammatory changes, as shown by Iba-1 immunostaining for microgliosis, were minimal around the infusion site. Sample brain in (F) showed the highest degree of damage from infusion, in this case from SNCA siRNA.